FDA approves anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma after 3 or more lines on or before the disclosed PDUFA goal date of 2026-12-23

The proposition

What was claimed

The FDA takes an approval action on the Biologics License Application for anitocabtagene autoleucel (anito-cel; applicant Arcellx, a Gilead Sciences subsidiary since April 2026) for the treatment of patients with relapsed or refractory multiple myeloma in the fourth line or later, with an approval action date on or before 2026-12-23, the PDUFA target action date disclosed in Gilead Sciences' Form 10-Q filed 2026-08-06.

Authority

US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) (US)

Target rungA step on the 12-rung ladder: rungs 1 to 4 are the evidence moving, rungs 5 to 7 are a guideline body, regulator, or payer acting. The ladder, rung by rung

Rung 6: Regulatory action — Label/indication change, approval action, REMS modification, or withdrawal by FDA, EMA, PMDA, Health Canada, etc.

Forecast classThe group of like forecasts this one is counted and scored with, such as FDA actions by their goal dates

FDA action by goal date

Scope

Relapsed or refractory multiple myeloma after 3 or more lines

The clock

Dates that constrain the record

resolution window

Today

Evidence cutoff2026-10-15 Registered2026-10-15 Window opens2026-10-16 Deadline2026-12-23

Evidence cutoff

2026-10-15

Registered

2026-10-15

Window opens

2026-10-16

Deadline

2026-12-23

Evidence cutoff

2026-10-15
Nothing after this date informed the estimate.

Registered

2026-10-15
Frozen and hashed.

Resolution window

2026-10-16 → 2026-12-23
When the adjudicator can read the outcome.

Event by

2026-12-23
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar

ledger 9f476a053fbff5ae6708d1471fa3d3dedd96b3a9a3e75f53b0d346ae088a458b Copy · operator record jc-1792036247345-3b14af2b

Resolution

The rule that settles the forecast

Anitocabtagene autoleucel is a CBER-regulated biologic, so openFDA's drugsfda endpoint does not list it. Resolves YES if FDA's Purple Book (https://purplebooksearch.fda.gov/) lists a licensed biological product that is anitocabtagene autoleucel (anito-cel) under any proprietary or proper name, with Arcellx, Kite or another Gilead Sciences subsidiary as licensee and an approval (license) date on or before 2026-12-23, and the CBER approval letter for that BLA names relapsed or refractory multiple myeloma in the indication. An approval after a different number of prior lines than the applicant sought, or for a narrower relapsed or refractory multiple myeloma population, still resolves YES. Resolves NO if no approval action is dated on or before 2026-12-23: a complete response letter, a goal-date extension, withdrawal or no action. The goal date is frozen as disclosed at the cutoff; a later extension does not move it, and an approval dated after 2026-12-23 resolves NO as occurred_after_deadline. Read no earlier than 2027-01-06. If the Purple Book has not updated by then, the CBER approval letter or FDA's list of approved products (https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) governs. Resolves unresolvable only if none of these can be read after the read floor. Resolves VOID, with the reason recorded, only if FDA withdraws every public record of approval actions named above without an equivalent public successor, so that no approval date for this product can be read; while any of them publishes it, the rule stands.

Source the rule names: https://purplebooksearch.fda.gov/, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

Readers: Resolver A, clinical methodology; Resolver B, payer evidence. The same two reader roles are assigned to every forecast registered so far.

What this record will show once it resolves

Frozen covariatesThe facts about the evidence and the authority's process that were frozen with the forecast at its cutoff

The state of the record at the cutoff

Recorded as they stood on 2026-10-15.

review pathway

Not stated in the archived sources. BLA submitted December 23, 2025 with an anticipated PDUFA date of December 23, 2026 (SRC-003); a 12-month timeline is consistent with a standard review (drafter's understanding, unverified). CBER center is the drafter's understanding for an autologous CAR-T product, unverified.

submission type

Original BLA (SRC-003).

evidence class

Single-arm pivotal Phase 2 iMMagine-1 in fourth-line-or-later rrMM, supported by a Phase 1 study (SRC-003, SRC-004).

pivotal n

iMMagine-1: 117 patients (ORR 96%, CR/sCR 74% as reported by Arcellx) (SRC-003).

endpoint type

Overall response rate, the primary endpoint of the single-arm iMMagine-1 trial, selected on CAR-T precedent and agreed with FDA (SRC-003); key secondary endpoints sCR/CR rate and duration of response (SRC-003).

approved competitors in class

Two FDA-approved BCMA-targeted CAR-T therapies: Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) (SRC-003; both listed on the CBER approved products page, SRC-005).

months since last guideline revision

not applicable — no guideline is the subject of this proposition

panel cycle position

not applicable — the act is an FDA approval action

sponsor request status

BLA submitted December 23, 2025; FDA accepted it February 20, 2026 (SRC-003).

odac referral

none announced in the archived sources

sponsor state change

Gilead closed its acquisition of Arcellx in April 2026 (~$6.4 billion); Arcellx became a wholly-owned subsidiary (SRC-001). Gilead's Kite was already the co-development/co-commercialization partner (SRC-003).